Brought to you by 
LogicBio's initial public offering nets $74.9mm
24 Oct 2018
Executive Summary
LogicBio Therapeutics Inc. (gene editing) netted $74.9mm through its initial public offering of 8mm common shares (including the overallotment) at $10. The company originally intended to sell 5.77mm shares for $12-14.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Transgenics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LogicBio's initial public offering nets $74.9mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice